TARSUS PHARMACEUTICALS, INC. Accumulated Other Comprehensive Income
TARSUS PHARMACEUTICALS, INC. (TARS) had Accumulated Other Comprehensive Income of -$557.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$557.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$298.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $381.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $289.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$557.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$298.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $381.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $289.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $39.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $85.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $179.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $346.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$176.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$63.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$2.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$8.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$23.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$70.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$74.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$10.00K 10-Q · filed 2022-11-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |